These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 34961705)

  • 1. Safety and pharmacokinetics of Roscovitine (Seliciclib) in cystic fibrosis patients chronically infected with Pseudomonas aeruginosa, a randomized, placebo-controlled study.
    Meijer L; Hery-Arnaud G; Leven C; Nowak E; Hillion S; Renaudineau Y; Durieu I; Chiron R; Prevotat A; Fajac I; Hubert D; Murris-Espin M; Huge S; Danner-Boucher I; Ravoninjatovo B; Leroy S; Macey J; Urban T; Rault G; Mottier D; Berre RL
    J Cyst Fibros; 2022 May; 21(3):529-536. PubMed ID: 34961705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. (R)-Roscovitine and CFTR modulators enhance killing of multi-drug resistant Burkholderia cenocepacia by cystic fibrosis macrophages.
    Shrestha CL; Zhang S; Wisniewski B; Häfner S; Elie J; Meijer L; Kopp BT
    Sci Rep; 2020 Dec; 10(1):21700. PubMed ID: 33303916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-Linear Pharmacokinetics of Oral Roscovitine (Seliciclib) in Cystic Fibrosis Patients Chronically Infected with
    Leven C; Schutz S; Audrezet MP; Nowak E; Meijer L; Montier T
    Pharmaceutics; 2020 Nov; 12(11):. PubMed ID: 33198319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa.
    Jain R; Beckett VV; Konstan MW; Accurso FJ; Burns JL; Mayer-Hamblett N; Milla C; VanDevanter DR; Chmiel JF;
    J Cyst Fibros; 2018 Jul; 17(4):484-491. PubMed ID: 29292092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients.
    Flume PA; VanDevanter DR; Morgan EE; Dudley MN; Loutit JS; Bell SC; Kerem E; Fischer R; Smyth AR; Aaron SD; Conrad D; Geller DE; Elborn JS
    J Cyst Fibros; 2016 Jul; 15(4):495-502. PubMed ID: 26852040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulating Innate and Adaptive Immunity by (R)-Roscovitine: Potential Therapeutic Opportunity in Cystic Fibrosis.
    Meijer L; Nelson DJ; Riazanski V; Gabdoulkhakova AG; Hery-Arnaud G; Le Berre R; Loaëc N; Oumata N; Galons H; Nowak E; Gueganton L; Dorothée G; Prochazkova M; Hall B; Kulkarni AB; Gray RD; Rossi AG; Witko-Sarsat V; Norez C; Becq F; Ravel D; Mottier D; Rault G
    J Innate Immun; 2016; 8(4):330-49. PubMed ID: 26987072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.
    Sutharsan S; McKone EF; Downey DG; Duckers J; MacGregor G; Tullis E; Van Braeckel E; Wainwright CE; Watson D; Ahluwalia N; Bruinsma BG; Harris C; Lam AP; Lou Y; Moskowitz SM; Tian S; Yuan J; Waltz D; Mall MA;
    Lancet Respir Med; 2022 Mar; 10(3):267-277. PubMed ID: 34942085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial.
    Ratjen F; Hug C; Marigowda G; Tian S; Huang X; Stanojevic S; Milla CE; Robinson PD; Waltz D; Davies JC;
    Lancet Respir Med; 2017 Jul; 5(7):557-567. PubMed ID: 28606620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial.
    Saiman L; Marshall BC; Mayer-Hamblett N; Burns JL; Quittner AL; Cibene DA; Coquillette S; Fieberg AY; Accurso FJ; Campbell PW;
    JAMA; 2003 Oct; 290(13):1749-56. PubMed ID: 14519709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection.
    Clancy JP; Dupont L; Konstan MW; Billings J; Fustik S; Goss CH; Lymp J; Minic P; Quittner AL; Rubenstein RC; Young KR; Saiman L; Burns JL; Govan JR; Ramsey B; Gupta R;
    Thorax; 2013 Sep; 68(9):818-25. PubMed ID: 23749840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining Ivacaftor and Intensive Antibiotics Achieves Limited Clearance of Cystic Fibrosis Infections.
    Durfey SL; Pipavath S; Li A; Vo AT; Ratjen A; Carter S; Morgan SJ; Radey MC; Grogan B; Salipante SJ; Welsh MJ; Stoltz DA; Goss CH; McKone EF; Singh PK
    mBio; 2021 Dec; 12(6):e0314821. PubMed ID: 34903059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study.
    Chuchalin A; Csiszér E; Gyurkovics K; Bartnicka MT; Sands D; Kapranov N; Varoli G; Monici Preti PA; Mazurek H
    Paediatr Drugs; 2007; 9 Suppl 1():21-31. PubMed ID: 17536872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous or oral antibiotic treatment in adults and children with cystic fibrosis and Pseudomonas aeruginosa infection: the TORPEDO-CF RCT.
    Langton Hewer SC; Smyth AR; Brown M; Jones AP; Hickey H; Kenna D; Ashby D; Thompson A; Sutton L; Clayton D; Arch B; Tanajewski Ł; Berdunov V; Williamson PR
    Health Technol Assess; 2021 Nov; 25(65):1-128. PubMed ID: 34806975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis.
    McCoy KS; Quittner AL; Oermann CM; Gibson RL; Retsch-Bogart GZ; Montgomery AB
    Am J Respir Crit Care Med; 2008 Nov; 178(9):921-8. PubMed ID: 18658109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leukotriene receptor antagonists in children with cystic fibrosis lung disease : anti-inflammatory and clinical effects.
    Schmitt-Grohé S; Zielen S
    Paediatr Drugs; 2005; 7(6):353-63. PubMed ID: 16356023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cysteamine re-establishes the clearance of Pseudomonas aeruginosa by macrophages bearing the cystic fibrosis-relevant F508del-CFTR mutation.
    Ferrari E; Monzani R; Villella VR; Esposito S; Saluzzo F; Rossin F; D'Eletto M; Tosco A; De Gregorio F; Izzo V; Maiuri MC; Kroemer G; Raia V; Maiuri L
    Cell Death Dis; 2017 Jan; 8(1):e2544. PubMed ID: 28079883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pseudomonas aeruginosa Reduces VX-809 Stimulated F508del-CFTR Chloride Secretion by Airway Epithelial Cells.
    Stanton BA; Coutermarsh B; Barnaby R; Hogan D
    PLoS One; 2015; 10(5):e0127742. PubMed ID: 26018799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CFTR activity is enhanced by the novel corrector GLPG2222, given with and without ivacaftor in two randomized trials.
    Bell SC; Barry PJ; De Boeck K; Drevinek P; Elborn JS; Plant BJ; Minić P; Van Braeckel E; Verhulst S; Muller K; Kanters D; Bellaire S; de Kock H; Geller DE; Conrath K; Van de Steen O; van der Ent K
    J Cyst Fibros; 2019 Sep; 18(5):700-707. PubMed ID: 31056441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa.
    Lenoir G; Antypkin YG; Miano A; Moretti P; Zanda M; Varoli G; Monici Preti PA; Aryayev NL
    Paediatr Drugs; 2007; 9 Suppl 1():11-20. PubMed ID: 17536871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase 3, randomized, double-blind, parallel-group study to evaluate tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for F508del-CFTR and a gating mutation.
    McKone EF; DiMango EA; Sutharsan S; Barto TL; Campbell D; Ahluwalia N; Higgins M; Owen CA; Tullis E
    J Cyst Fibros; 2021 Mar; 20(2):234-242. PubMed ID: 33339768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.